OCUP: Ocuphire Pharma, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 62.07
Enterprise Value ($M) 19.72
Book Value ($M) 50.28
Book Value / Share 2.09
Price / Book 1.23
NCAV ($M) 50.28
NCAV / Share 2.09
Price / NCAV 1.23

Profitability (mra)
Return on Invested Capital (ROIC) 0.57
Return on Assets (ROA) 0.59
Return on Equity (ROE) 0.62

Liquidity (mrq)
Quick Ratio 13.86
Current Ratio 13.86

Balance Sheet (mrq) ($M)
Current Assets 54.19
Assets 54.19
Liabilities 3.91
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
2023-02-14 13G/A Sooch Mina 5.50 -7.69

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 ☐ TRANSITION REPORT
2023-08-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 ☐ TRANSITION REPORT PURS
2023-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 ☐ TRANSITION REPORT PUR
2023-03-30 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-02-21 47,607 234,624 20.29
2024-02-20 35,979 115,171 31.24
2024-02-16 12,972 75,460 17.19

(click for more detail)

Similar Companies
NVCT – Nuvectis Pharma, Inc. OCEA – Ocean Biomedical, Inc.
OCGN – Ocugen, Inc. OCX – OncoCyte Corporation
OKYO – OKYO Pharma Limited


Financial data and stock pages provided by
Fintel.io